Invesco Ltd. Sells 1,442,488 Shares of Medtronic PLC $MDT

Invesco Ltd. trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 8.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,204,661 shares of the medical technology company’s stock after selling 1,442,488 shares during the quarter. Invesco Ltd. owned approximately 1.26% of Medtronic worth $1,543,332,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MDT. Seven Mile Advisory lifted its stake in shares of Medtronic by 85.3% during the 3rd quarter. Seven Mile Advisory now owns 4,757 shares of the medical technology company’s stock worth $453,000 after purchasing an additional 2,190 shares during the last quarter. Employees Retirement System of Texas boosted its position in Medtronic by 1,117.0% during the third quarter. Employees Retirement System of Texas now owns 891,232 shares of the medical technology company’s stock valued at $84,881,000 after purchasing an additional 818,000 shares in the last quarter. Sei Investments Co. grew its stake in Medtronic by 0.7% in the third quarter. Sei Investments Co. now owns 1,036,749 shares of the medical technology company’s stock valued at $98,743,000 after purchasing an additional 7,498 shares during the last quarter. Crux Wealth Advisors grew its stake in Medtronic by 4.4% in the third quarter. Crux Wealth Advisors now owns 15,725 shares of the medical technology company’s stock valued at $1,498,000 after purchasing an additional 667 shares during the last quarter. Finally, SageView Advisory Group LLC raised its holdings in Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after purchasing an additional 15,062 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of MDT stock opened at $87.50 on Friday. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market capitalization of $112.34 billion, a price-to-earnings ratio of 24.37, a PEG ratio of 2.28 and a beta of 0.71. The stock’s 50-day simple moving average is $98.14 and its 200-day simple moving average is $96.87.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analyst Upgrades and Downgrades

Several analysts have commented on MDT shares. Barclays reissued an “overweight” rating and set a $118.00 price target on shares of Medtronic in a research report on Wednesday, February 18th. CICC Research assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price for the company. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Finally, Robert W. Baird cut their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).